Applied DNA Sciences (NASDAQ:APDN) Now Covered by Analysts at StockNews.com

Posted by on Jun 6th, 2023

Equities researchers at StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN – Get Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the technology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Applied DNA Sciences in a research report on Thursday, March 30th.

Applied DNA Sciences Trading Down 0.8 %

NASDAQ:APDN opened at $1.25 on Tuesday. Applied DNA Sciences has a 12 month low of $0.62 and a 12 month high of $7.35. The firm has a fifty day simple moving average of $1.08 and a 200-day simple moving average of $1.31.

Applied DNA Sciences (NASDAQ:APDN – Get Rating) last posted its quarterly earnings data on Thursday, May 11th. The technology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Applied DNA Sciences had a negative return on equity of 82.08% and a negative net margin of 28.78%. The company had revenue of $4.41 million for the quarter, compared to analyst estimates of $4.20 million. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. On average, sell-side analysts predict that Applied DNA Sciences will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Applied DNA Sciences by 67.3% in the third quarter. Vanguard Group Inc. now owns 353,050 shares of the technology company’s stock valued at $399,000 after buying an additional 142,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in Applied DNA Sciences by 28.8% in the fourth quarter. Geode Capital Management LLC now owns 129,355 shares of the technology company’s stock valued at $214,000 after buying an additional 28,897 shares in the last quarter. Two Sigma Investments LP purchased a new position in Applied DNA Sciences in the third quarter valued at $146,000. BlackRock Inc. increased its holdings in Applied DNA Sciences by 63.7% in the third quarter. BlackRock Inc. now owns 101,661 shares of the technology company’s stock valued at $114,000 after buying an additional 39,541 shares in the last quarter. Finally, Cowen Prime Advisors LLC purchased a new position in Applied DNA Sciences in the fourth quarter valued at $163,000. Hedge funds and other institutional investors own 15.27% of the company’s stock.

About Applied DNA Sciences

(Get Rating)

Applied DNA Sciences, Inc engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics.

Recommended Stories

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.